CTOs on the Move

Sagimet

www.sagimet.com

 
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.sagimet.com
  • 155 Bovet Road, Suite 303
    San Mateo, CA USA 94402
  • Phone: 650.561.8600

Executives

Name Title Contact Details

Funding

Sagimet raised 2/11/2021 on 00/00/0000

Similar Companies

Sanford House

Sanford House in Grand Rapids, Michigan is a drug and alcohol rehab and recovery center. We offer residential and non-residential treatment options for both men and women in Michigan and across the country. Our Johns Street location provides detox for ...

Sara Wasserbauer M.D.

Hair Transplant Surgery and medical hair loss treatments by hair surgeon Sara Wasserbauer, M.D.. Medical Hair Restoration services. Medical Hair Loss Treatments, in Walnut Creek, San Jose, San Francisco and Napa, California.(CA)

Division of Industry Dynamics Associates

Division of Industry Dynamics Associates is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agile Therapeutics

Agile Therapeutics is a forward-thinking women`s healthcare company dedicated to fulfilling the unmet health needs of today`s women. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Twirla® and our pipeline products are based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.